The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Xigduo dapagliflozin;metformin | AstraZeneca AB | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2014-01-16 | Order → |
| Zoledronic Acid Accord zoledronic acid Generic | Accord Healthcare S.L.U. | Hypercalcemia; Fractures, Bone; Cancer | 🇪🇺 EU 2014-01-16 | Order → |
| Levetiracetam Hospira levetiracetam Generic | Pfizer Europe MA EEIG | Epilepsy | 🇪🇺 EU 2014-01-07 | Order → |
| Opsumit macitentan | Hypertension, Pulmonary | 🇪🇺 EU 2013-12-20 | Order → | |
| Brintellix vortioxetine | H. Lundbeck A/S | Depressive Disorder, Major | 🇪🇺 EU 2013-12-18 | Order → |
| Fluenz Tetra influenza vaccine (live attenuated, nasal) | AstraZeneca AB | Influenza, Human | 🇪🇺 EU 2013-12-04 | Order → |
| Memantine Accord memantine Generic | Accord Healthcare S.L.U. | Alzheimer Disease | 🇪🇺 EU 2013-12-03 | Order → |
| Fortacin lidocaine;prilocaine | Recordati Ireland Ltd. | Sexual Dysfunction, Physiological | 🇪🇺 EU 2013-11-15 | Order → |
| Invokana canagliflozin | Janssen-Cilag International NV | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2013-11-15 | Order → |
| Kadcyla trastuzumab emtansine | Roche Registration GmbH | Breast Neoplasms | 🇪🇺 EU 2013-11-15 | Order → |
| Abilify Maintena aripiprazole | Otsuka Pharmaceutical Netherlands B.V. | Schizophrenia | 🇪🇺 EU 2013-11-14 | Order → |
| NovoEight turoctocog alfa | Novo Nordisk A/S | Hemophilia A | 🇪🇺 EU 2013-11-13 | Order → |
| Relvar Ellipta fluticasone furoate;vilanterol | GlaxoSmithKline Trading Services Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2013-11-13 | Order → |
| Vitekta elvitegravir Additional monitoring | Gilead Sciences International Ltd | HIV Infections | 🇪🇺 EU 2013-11-13 | Order → |
| Xofigo radium Ra223 dichloride Additional monitoring | Bayer AG | Prostatic Neoplasms | 🇪🇺 EU 2013-11-13 | Order → |
| Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) levodopa;carbidopa;entacapone | Orion Corporation | Parkinson Disease | 🇪🇺 EU 2013-11-11 | Order → |
| Defitelio defibrotide Exceptional circumstancesAdditional monitoring | Gentium S.r.l. | Hepatic Veno-Occlusive Disease | 🇪🇺 EU 2013-10-18 | Order → |
| Grastofil filgrastim Biosimilar | Accord Healthcare S.L.U. | 🇪🇺 EU 2013-10-18 | Order → | |
| Ovaleap follitropin alfa Biosimilar | Theramex Ireland Limited | Anovulation | 🇪🇺 EU 2013-09-27 | Order → |
| Evarrest human fibrinogen;human thrombin Additional monitoring | Omrix Biopharmaceuticals N. V. | Hemostasis | 🇪🇺 EU 2013-09-25 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.